

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	glecaprevir-pibrentasvir
Brand Name	Maviret™
Dosage Form(s)	100 mg/40 mg tablet
Manufacturer	AbbVie Corporation
Submission Type	New Submission
Use Reviewed	For the treatment of chronic hepatitis C (CHC)
Common Drug Review (CDR)	Yes, CDR recommended: to Reimburse with clinical criteria and/or conditions . Visit the CDR website for more details: https://www.cadth.ca/sites/default/files/cdr/complete/SR0523_Maviret_complete-Jan-25-18.pdf
Provincial Review	The DBC now screens drug submissions under review by the CDR to determine whether or not a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry's drug coverage decision will be based on the CDEC recommendation and an internal review only. The DBC screened Maviret™ on November 6, 2017. The DBC advised that because glecaprevir-pibrentasvir is similar to some of the other drugs used for the treatment of CHC, the Ministry may accept the CDEC's recommendation for glecaprevir-pibrentasvir.
Drug Coverage Decision	Limited Coverage Benefit. Access the glecaprevir-pibrentasvir criteria from www.gov.bc.ca/pharmacarespecialauthority
Date	January 29, 2019
Reason(s)	<p>Drug coverage decision is consistent with CDEC recommendation.</p> <ul style="list-style-type: none"> • Maviret™ reported high cure rates (based upon sustained viral response), is generally well-tolerated, and offers a shorter 8 weeks duration of therapy for treatment-naïve CHC patients without cirrhosis. • Based on economic considerations and the submitted product price, Maviret™ was not cost effective and/or did not offer optimal value for money. • The Ministry participated in the pan-Canadian Pharmaceutical Alliance negotiations with the manufacturer, which were able to address the concerns identified by the CDEC with respect to cost-effectiveness and value for money. • Effective January 29, 2019, PharmaCare will provide coverage for Maviret™ with the following criteria: <ul style="list-style-type: none"> ○ for adult patients with CHC genotype 2, 3, 5, or 6 infection with or without compensated cirrhosis, and who have severe kidney disease or end-stage kidney disease (including patients on dialysis); and ○ for adult patients with CHC genotype 1 infection who were previously treated with direct-acting antivirals (DAA) and who have severe kidney disease or end-stage kidney disease (including patients on dialysis).
Other Information	None

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit the [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.